A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
While there are several SARS-CoV-2 vaccines currently available, additional options must be provided that are safe, effective, and affordable for the entire global population. We have developed a novel immune activating platform technology that will fill this need. This recombinant platform protein...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2062971 |
| _version_ | 1797673204940013568 |
|---|---|
| author | Edward J. Quinlan Richard Chubet Peter Leonardi |
| author_facet | Edward J. Quinlan Richard Chubet Peter Leonardi |
| author_sort | Edward J. Quinlan |
| collection | DOAJ |
| description | While there are several SARS-CoV-2 vaccines currently available, additional options must be provided that are safe, effective, and affordable for the entire global population. We have developed a novel immune activating platform technology that will fill this need. This recombinant platform protein is produced in insect cells using baculoviral expression technology similar to what is currently used for several other approved vaccines as well as employed by myriad GMP facilities globally. Thus, infrastructure exists for rapid scale up following initial optimizations. Here we report initial results for a SARS-CoV-2 vaccine (OMN008) based on our platform technology. Unadjuvanted OMN008 vaccination resulted in robust antigenicity and neutralization. Additionally, OMN008 vaccination induced a specific CD8 T-cell response. All of these results taken together indicate OMN008 may be an excellent candidate to fill gaps left by the currently available vaccines. Further testing is necessary to fully optimize production; however, overall cost of production should remain low given the simple formulation of this recombinant platform. |
| first_indexed | 2024-03-11T21:40:53Z |
| format | Article |
| id | doaj.art-a81593c2cee547ceb8098406793dc9fc |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:53Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-a81593c2cee547ceb8098406793dc9fc2023-09-26T13:19:06ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118410.1080/21645515.2022.20629712062971A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technologyEdward J. Quinlan0Richard Chubet1Peter Leonardi2OmniCyte LLCOmniCyte LLCOmniCyte LLCWhile there are several SARS-CoV-2 vaccines currently available, additional options must be provided that are safe, effective, and affordable for the entire global population. We have developed a novel immune activating platform technology that will fill this need. This recombinant platform protein is produced in insect cells using baculoviral expression technology similar to what is currently used for several other approved vaccines as well as employed by myriad GMP facilities globally. Thus, infrastructure exists for rapid scale up following initial optimizations. Here we report initial results for a SARS-CoV-2 vaccine (OMN008) based on our platform technology. Unadjuvanted OMN008 vaccination resulted in robust antigenicity and neutralization. Additionally, OMN008 vaccination induced a specific CD8 T-cell response. All of these results taken together indicate OMN008 may be an excellent candidate to fill gaps left by the currently available vaccines. Further testing is necessary to fully optimize production; however, overall cost of production should remain low given the simple formulation of this recombinant platform.http://dx.doi.org/10.1080/21645515.2022.2062971sars-cov-2vaccinet-cellbaculovirussubunitdendritic celldc-sign |
| spellingShingle | Edward J. Quinlan Richard Chubet Peter Leonardi A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology Human Vaccines & Immunotherapeutics sars-cov-2 vaccine t-cell baculovirus subunit dendritic cell dc-sign |
| title | A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology |
| title_full | A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology |
| title_fullStr | A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology |
| title_full_unstemmed | A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology |
| title_short | A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology |
| title_sort | novel sars cov 2 subunit vaccine engineered on an immune activating platform technology |
| topic | sars-cov-2 vaccine t-cell baculovirus subunit dendritic cell dc-sign |
| url | http://dx.doi.org/10.1080/21645515.2022.2062971 |
| work_keys_str_mv | AT edwardjquinlan anovelsarscov2subunitvaccineengineeredonanimmuneactivatingplatformtechnology AT richardchubet anovelsarscov2subunitvaccineengineeredonanimmuneactivatingplatformtechnology AT peterleonardi anovelsarscov2subunitvaccineengineeredonanimmuneactivatingplatformtechnology AT edwardjquinlan novelsarscov2subunitvaccineengineeredonanimmuneactivatingplatformtechnology AT richardchubet novelsarscov2subunitvaccineengineeredonanimmuneactivatingplatformtechnology AT peterleonardi novelsarscov2subunitvaccineengineeredonanimmuneactivatingplatformtechnology |